PE20030665A1 - ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a - Google Patents

ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a

Info

Publication number
PE20030665A1
PE20030665A1 PE2002001143A PE2002001143A PE20030665A1 PE 20030665 A1 PE20030665 A1 PE 20030665A1 PE 2002001143 A PE2002001143 A PE 2002001143A PE 2002001143 A PE2002001143 A PE 2002001143A PE 20030665 A1 PE20030665 A1 PE 20030665A1
Authority
PE
Peru
Prior art keywords
aryl
inhibitors
adenosine
azepanil
piperidinyl
Prior art date
Application number
PE2002001143A
Other languages
English (en)
Spanish (es)
Inventor
Craig D Boyle
Samuel Chackalamannil
Yan Xia
Unmesh G Shah
William J Greenlee
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20030665A1 publication Critical patent/PE20030665A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2002001143A 2001-11-30 2002-11-27 ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a PE20030665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33434201P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
PE20030665A1 true PE20030665A1 (es) 2003-08-08

Family

ID=23306779

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001143A PE20030665A1 (es) 2001-11-30 2002-11-27 ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a

Country Status (18)

Country Link
US (1) US6916811B2 (enExample)
EP (1) EP1448565B1 (enExample)
JP (2) JP4284182B2 (enExample)
KR (1) KR20050044593A (enExample)
CN (1) CN1692116A (enExample)
AR (1) AR037680A1 (enExample)
AT (1) ATE453647T1 (enExample)
AU (1) AU2002346503A1 (enExample)
CA (1) CA2468649C (enExample)
DE (1) DE60234951D1 (enExample)
ES (1) ES2336435T3 (enExample)
HU (1) HUP0402018A3 (enExample)
IL (1) IL161716A0 (enExample)
MX (1) MXPA04005209A (enExample)
PE (1) PE20030665A1 (enExample)
TW (1) TW200306837A (enExample)
WO (1) WO2003048165A1 (enExample)
ZA (1) ZA200404161B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4574112B2 (ja) * 2000-05-26 2010-11-04 シェーリング コーポレイション アデノシンa2aレセプターアンタゴニスト
US6964288B2 (en) * 2001-07-06 2005-11-15 Ksaria Corporation Apparatus and method for automated preparation of an optical fiber
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンa2a受容体アンタゴニストとしてのイミダゾ(4,3−e)−1,2,4−トリアゾロ(1,5−c)ピリミジン
US7064204B2 (en) * 2002-05-30 2006-06-20 King Pharmacueticals Reserch And Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
WO2005044245A1 (en) * 2002-12-19 2005-05-19 Schering Corporation USES OF ADENOSINE A2a RECEPTOR ANTAGONISTS
JP4800216B2 (ja) * 2003-10-24 2011-10-26 エグゼリクシス, インコーポレイテッド p70S6キナーゼモジュレーターおよび使用方法
WO2005044819A1 (en) * 2003-10-28 2005-05-19 Schering Corporation Process for preparing substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
ATE516011T1 (de) * 2003-12-19 2011-07-15 Schering Corp Pharmazeutische zusammensetzungen eines a2a rezeptorantagonisten
EP2258372B8 (en) * 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
WO2009078999A1 (en) 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
HRP20141047T1 (hr) 2008-08-01 2015-01-02 Eye Therapies Llc Pripravci za sužavanje krvnih žila i metode njihove uporabe
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
EP2379556A1 (en) 2008-12-30 2011-10-26 ArQule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
WO2010114894A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
CN113015530A (zh) 2018-11-20 2021-06-22 默沙东公司 取代的氨基三唑并嘧啶和氨基三唑并吡嗪腺苷受体拮抗剂、药物组合物及其用途
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
KR20210097152A (ko) 2018-11-30 2021-08-06 머크 샤프 앤드 돔 코포레이션 아데노신 수용체 길항제로서의 7-, 8- 및 10-치환된 아미노 트리아졸로 퀴나졸린 유도체, 제약 조성물 및 그의 용도
JOP20210117A1 (ar) 2018-11-30 2023-01-30 Merck Sharp & Dohme مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
EP3999513A4 (en) * 2019-07-17 2022-12-21 Teon Therapeutics, Inc. ADENOSIN A2A RECEPTOR ANTAGONISTS AND USES THEREOF
CN112625050B (zh) 2019-07-30 2021-10-01 杭州阿诺生物医药科技有限公司 一种a2a和/或a2b受体抑制剂的制备方法
CN112608316B (zh) 2019-07-30 2022-10-21 厦门宝太生物科技股份有限公司 一种吡唑并三嗪类腺苷受体拮抗剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) * 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1277392B1 (it) * 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
JP4574112B2 (ja) 2000-05-26 2010-11-04 シェーリング コーポレイション アデノシンa2aレセプターアンタゴニスト
US7064204B2 (en) * 2002-05-30 2006-06-20 King Pharmacueticals Reserch And Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
MXPA05011366A (es) * 2003-04-23 2005-11-28 Schering Corp Antagonistas del receptor a2a de 2-alquinil- y 2-alquenil-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidina adenosina.

Also Published As

Publication number Publication date
US6916811B2 (en) 2005-07-12
AR037680A1 (es) 2004-12-01
WO2003048165A1 (en) 2003-06-12
DE60234951D1 (de) 2010-02-11
US20030212059A1 (en) 2003-11-13
EP1448565A1 (en) 2004-08-25
HK1063780A1 (en) 2005-01-14
KR20050044593A (ko) 2005-05-12
CN1692116A (zh) 2005-11-02
EP1448565B1 (en) 2009-12-30
JP2008260776A (ja) 2008-10-30
ZA200404161B (en) 2005-11-30
IL161716A0 (en) 2004-09-27
HUP0402018A2 (hu) 2005-02-28
TW200306837A (en) 2003-12-01
CA2468649C (en) 2009-03-10
CA2468649A1 (en) 2003-06-12
AU2002346503A1 (en) 2003-06-17
HUP0402018A3 (en) 2008-06-30
MXPA04005209A (es) 2004-08-19
JP2005511699A (ja) 2005-04-28
JP4284182B2 (ja) 2009-06-24
ES2336435T3 (es) 2010-04-13
ATE453647T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
PE20030665A1 (es) ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20060873A1 (es) Compuestos de quinolina heteroaromaticos
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
CY1114022T1 (el) Φαρμακα με δραση υποδοχεα ημ74α
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
ECSP056072A (es) Pirimidinonas sustituidas
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
SG166019A1 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
UY28150A1 (es) Agentes terapeuticos
PE20070832A1 (es) Derivados de piridazinona como inhibidores de la tirosina quinasa
DE60318583D1 (de) N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
AR052312A1 (es) 2- anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y medicamentos preparados en base al compuesto
DE60123933D1 (de) Fluoreszierende proben zur quantitativen bestimmung von zink
PA8581401A1 (es) Compuestos de imedazopiridina como agonistas del receptor 5-ht4
PE20050141A1 (es) DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA
TW200508359A (en) Quinoxaline derivatives, and light emitting element using thereof
PA8575001A1 (es) Fluorobenzamidas como inhibidores de maob
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
PE20061378A1 (es) INHIBIDORES DE LA ACTIVIDAD DE Akt

Legal Events

Date Code Title Description
FC Refusal